RT Journal Article
SR Electronic
T1 Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.12.21267695
DO 10.1101/2021.12.12.21267695
A1 Nantanee, Rapisa
A1 Aikphaibul, Puneyavee
A1 Jaru-Ampornpan, Peera
A1 Sodsai, Pimpayao
A1 Himananto, Orawan
A1 Theerawit, Tuangtip
A1 Sophonphan, Jiratchaya
A1 Tovichayathamrong, Punyot
A1 Manothummetha, Kasama
A1 Laohasereekul, Tysdi
A1 Hiransuthikul, Narin
A1 Hirankarn, Nattiya
A1 Puthanakit, Thanyawee
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/12/23/2021.12.12.21267695.abstract
AB Background Currently, booster dose is needed after 2 doses of inactivated COVID-19 vaccine. With limited resource and shortage of COVID-19 vaccine, intradermal(ID) administration might be a potential dose-sparing strategy.Objective To determine antibody response and reactogenicity of ID ChAdOx1 nCoV-19 vaccine(AZD1222,Oxford/AstraZeneca) as a booster dose after completion of 2-dose CoronaVac(SV) in healthy adult.Methods This is a prospective cohort study of adult aged 18-59 years who received 2-dose SV at 14-35 days apart for more than 2 months. Participants received ID AZD1222 at fractional low dose(1×1010 viral particles,0.1ml). Antibody responses were evaluated by surrogate virus neutralization test(sVNT) against wild type and delta variant and anti-spike-receptor-binding-domain immunoglobulin G(anti-S-RBD IgG) at prior, day14 or 28, and day90 post booster. Solicited reactogenicity was collected during 7 days post-booster. Primary endpoint was the differences of sVNT against delta strain ≥80%inhibition at day14 and 90 compared with the parallel cohort study of 0.5-ml intramuscular(IM) route.Results From August2021, 100 adults with median(IQR) age of 46(41-52) years participated. At baseline, geometric means(GMs) of sVNT against delta strain prior to booster were 22.4%inhibition(95%CI 18.7-26.9) and of anti-S-RBD IgG were 109.3(95.4-125.1)BAU/ml. GMs of sVNT against delta strain were 92.9%inhibition(95%CI 87.7-98.3) at day14 and 73.1%inhibition(66.7-80.2) at day90 post ID booster. The differences of proportion of participants with sVNT to delta strain≥80%inhibition in ID recipients versus IM were +4.2%(95%CI-2.0to10.5) at day14, and -37.3%(−54.2to−20.3) at day90. Anti-S-RBD IgG GMs were 2037.1(95%CI1770.9-2343.2) at day14 and 744.6(650.1-852.9) BAU/ml at day90, respectively. Geometric mean ratios(GMRs) of anti-S-RBD IgG were 0.99(0.83-1.20) at day14, and 0.82(0.66-1.02) at day90. Only 18% reported feverish, compared with 37% of IM(p=0.003). Only 18% reported feverish, compared with 37% of IM(p=0.003). Common reactogenicity was erythema(55%) at injection site while 7% reported blister.Conclusion Low-dose ID AZD1222 booster enhanced lower neutralizing antibodies at 3 months compared with IM route. Less systemic reactogenicity occurred, but higher local reactogenicity.HighlightsIntradermal AZD1222 booster vaccine gave comparable short-term immunogenicity but lower 90-day immunogenicity with conventional intramuscular vaccine.Lower systemic but higher local reactogenicity was found in intradermal AZD1222 booster vaccine.Blister and pruritus could be seen after intradermal AZD1222 booster vaccine.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study was registered in Thai Clinical Trials Registry (thaiclinicaltrials.org, TCTR 20210817003).Funding StatementThe study was funded by the Ratchadapisek Sompoch Endowment Fund (2021) under Health Research Platform (RA64/050), Chulalongkorn University. This research is also supported by Ratchadapisek Somphot Fund for Postdoctoral Fellowship, Chulalongkorn University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review board of Faculty of Medicine, Chulalongkorn University approved this study (IRB no. 663/64) and parallel IM AZD1222 booster study (IRB no. 600/64).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.BAUBinding-antibody unitBMIBody mass indexCMICell-mediated immunityELISpotEnzyme-linked immunospotGMGeometric meanGMRGeometric mean ratioIDIntradermalIMIntramuscularPBMCPeripheral blood mononuclear cellSFUSpot forming unitS-RBDSpike receptor binding domainsVNTSurrogate virus neutralization test